1. Home
  2. Programs
  3. Practical Dermatology

Practical Dermatology

  • Medical News
    Secukinumab Reduces Erosions in Psoriatic Arthritis Patients

    Key Takeaways

    • Secukinumab reduced erosion volume in psoriatic arthritis (PsA) patients over 48 weeks.
    • Enthesiophyte progression was less likely with secukinumab treatment (OR: 0.264; P = 0.030).
    • Odds of partial erosion healing were 2.9 times higher with secukinumab.

     

    Secukinumab significantly reduced erosion progression in patients with psoriatic arthritis (PsA), according to findings from a phase 4 randomized, double-blind, placebo-controlled trial.

    The study eva...

    03/20/2025
  • Medical News
    Psoriasis Pipeline: What's Here and What's Coming in Orals, Biologics, and Beyond

    At the 2025 American Academy of Dermatology Annual Meeting, Dr. Bruce E. Strober, MD, PhD, FAAD, a clinical professor of dermatology at Yale University School of Medicine, delivered a compelling presentation outlining transformative advancements in psoriasis treatment. These developments promise ...

    03/10/2025
  • Medical News
    3-Year Results: Sustained Psoriasis Treatment Goals Achieved with Risankizumab

    Key Takeaways

    • 96.2% of patients achieved NPF-defined acceptable responses after 36 months of risankizumab.
    • 86.1% maintained PASI 90 scores from 12 to 36 months.
    • 68.8% of patients reported minimal quality-of-life impact (DLQI = 0/1) after 36 months.

     

    New research presented at the 2025 American Academy of Dermatology Annual Meeting showed long-term treatment with risankizumab resulted in sustained skin clearance for most patients with moderate to s...

    03/10/2025
  • Medical News
    Analysis: Lower PsA Risk Linked to Psoriasis Treatment Target Achievement

    Key Takeaways

    • Achieving National Psoriasis Foundation treatment targets (BSA ≤1%) after starting biologics reduces the incidence of psoriatic arthritis (PsA) in psoriasis patients.
    • PsA incidence rates were 6.46 vs. 8.82 per 100 person-years for target achievers vs. non-achievers.
    • Study findings rei...

     

    Patients with psoriasis who achieve the National Psoriasis Foundation (NPF) treatment target after starting biologic therapy may experience a reduced risk of developing psoriatic arthritis (PsA), acco...

    03/10/2025
  • Medical News
    Get In First: A Derm's Case for Early Psoriasis Treatment

    Key Takeaways

    1. Early intervention in psoriasis can improve immediate quality of life, reduce the progression of comorbidities, and potentially extend longevity.
    2. Targeting IL-23 through biologics may disrupt disease pathways, enabling prolonged remission and even disease modification.
    3. Delaying treatm...

     

    Addressing psoriasis early in its course may lead to prolonged remission and better outcomes, and dermatologists should take note, according to a presentation at the 2025 American Academy of Dermatolo...

    03/08/2025
  • Medical News
    ICONIC-LEAD: Icotrokinra Clears Almost Half of Psoriasis Patients in Phase 3 Trial

    Key Takeaways

    • At week 24, 74% of icotrokinra-treated patients achieved IGA 0/1, and 65% reached PASI 90.
    • Almost half of patients achieved completely clear skin (IGA 0) by Week 24.
    • Adverse events were similar between icotrokinra and placebo groups, with no new safety signals.

     

    Nearly half of patients with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin at week 24, according to new data presented at the 2025 America Academy of Derm...

    03/08/2025
  • IPC
    Medical News
    IPC Comorbidities Symposium Covers Depression, Obesity, and More
    03/06/2025
  • Medical News
    Analysis: Biosimilars Show Comparable Effectiveness to Humira in Psoriasis

    Key Takeaways

    • Amjevita and Imraldi showed similar efficacy to Humira in achieving PASI ≤2 and PASI ≤4 at 12 months, according to this study.
    • The analysis included 11,400 psoriasis patients across two cohorts (new users and switchers).

     

    Adalimumab biosimilars Amjevita and Imraldi showed similar effectiveness to Humira for the treatment of psoriasis in both new users and patients switching from Humira, according to an analysis of the ...

    03/06/2025
  • Medical News
    Closing Gaps: Takeda Enhances Diversity in Psoriasis Trials

    Key Takeaways

    • Takeda’s U.S. psoriasis trials exceeded diversity goals, doubling Black and Hispanic enrollment, according to the manufacturer.
    • Asian representation in trials met targets after tailored outreach to communities.
    • Native American enrollment surpassed U.S. population representation, but f...

     

    Takeda’s phase 3 psoriasis (PsO) clinical trials in the United States achieved success in enhancing racial and ethnic diversity among participants, according to new data from the manufacturer. 

    Psoria...

    03/05/2025
  • Medical News
    Dr. Lain Discusses Predictive Modeling for PsO Biologic Selection

    Edward (Ted) Lain, MD, MBA, reminded attendees at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, that a method exists for selecting the best class of biologic for each psoriasis patient.

    “I just want to keep this in the public conscience here,” Dr. Lain said. “There is a way to...

    02/21/2025
  • Medical News
    Patient-Centric Guidelines for Generalized Pustular Psoriasis Management Unveiled

    Key Takeaways

    • The first global Delphi study on GPP treatment inccluded both physician and patient perspectives.
    • Consensus was reached on timely, multidisciplinary care, measurable treatment outcomes, and patient QoL improvements.
    • Short-term goals like rapid symptom relief, and long-term objectives ...

     

    A global Delphi study has established holistic treatment goals for generalized pustular psoriasis (GPP), integrating both physician and patient perspectives.

    The consensus study included participants ...

    02/21/2025
  • Medical News
    EFFISAYIL 2 Data Suggest Unmet Needs in Generalized Pustular Psoriasis Care

    Key Takeaways

    • EFFISAYIL 2 baseline data revealed that traditional small-molecule therapies leave most GPP patients with incomplete skin clearance and impaired quality of life.
    • More than 80% of patients across treatment groups began the trial with a GPPGA score of 1.

     

    Baseline data from the EFFISAYIL 2 trial suggested that traditional small-molecule therapies fail to adequately address the burden of generalized pustular psoriasis (GPP). 

    The analysis, presented as ...

    02/20/2025
  • Medical News
    Dr. Lebwohl: Don't Delay GPP Treatment for TB Testing or Skin Biopsy

    Generalized pustular psoriasis (GPP) treatment should not be delayed while waiting for a tuberculosis screening, according to Mark Lebwohl, MD.

    Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Lebwohl recommended initiating spesolimab therapy immediately upon susp...

    02/20/2025
  • Medical News
    Weight-Loss Drugs Highlighted as 'Easy' Option to Improve PsO Therapies

    Any dermatologist not prescribing weight-loss drugs for psoriasis patients who are obese likely will be soon, according to Mark Lebwohl, MD.

    Dr. Lebwohl, speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, highlighted data indicating an association between comorbid obesi...

    02/20/2025

    • Program Chapters

    Segment Chapters

    Playlist:

    Recommended

    Register

    We’re glad to see you’re enjoying ReachMD…
    but how about a more personalized experience?

    Register for free
    PrevNext